Comparative assessment of safety with leadless pacemakers compared to transvenous pacemakers: a systemic review and meta-analysis.


Journal

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing
ISSN: 1572-8595
Titre abrégé: J Interv Card Electrophysiol
Pays: Netherlands
ID NLM: 9708966

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 09 03 2023
accepted: 10 04 2023
medline: 5 12 2023
pubmed: 28 4 2023
entrez: 27 4 2023
Statut: ppublish

Résumé

Leadless pacemakers (LP) and transvenous pacemakers (TVP) are two stable pacing platforms currently available in clinical practice. Observational data show mixed results with regards to their comparative safety. This meta-analysis was aimed to evaluate the comparative safety of LP over TVP. The study protocol was registered in PROSPERO registry (CRD42022325376). Six databases were searched for published literature from inception to April 12, 2022. RevMan 5.4.1 was used for statistical analysis. Odds ratio (OR) and mean difference were used to estimate the outcome with a 95% confidence interval (CI). A total of 879 studies were imported from the databases. Among these, 41 papers were screened for full text and 17 meet the inclusion criteria. Among them, pooled results showed 42% lower odds of occurrence of complications in the LP group (OR 0.58, CI 0.42-0.80) compared to TVP group. Notably, 70% lower odds of device dislodgment (OR 0.30, CI 0.21-0.43), 46% lower odds of re-intervention (OR 0.54, CI 0.45-0.64), 87% lower odds of pneumothorax (OR 0.13, CI 0.03-0.57), albeit, 2.65 times higher odds of pericardial effusion (OR 2.65, CI 1.49-4.70) were observed in the LP group. This meta-analysis showed LP to be a significantly safer modality compared to TVP, in terms of re-intervention, device dislodgment, pneumothoraxes, and overall complications. However, there were higher rates of pericardial effusion in the LP group. There was a diverse number of patients included, and all studies were observational. Randomized trials are needed to validate our findings.

Sections du résumé

BACKGROUND BACKGROUND
Leadless pacemakers (LP) and transvenous pacemakers (TVP) are two stable pacing platforms currently available in clinical practice. Observational data show mixed results with regards to their comparative safety. This meta-analysis was aimed to evaluate the comparative safety of LP over TVP.
METHODS METHODS
The study protocol was registered in PROSPERO registry (CRD42022325376). Six databases were searched for published literature from inception to April 12, 2022. RevMan 5.4.1 was used for statistical analysis. Odds ratio (OR) and mean difference were used to estimate the outcome with a 95% confidence interval (CI).
RESULTS RESULTS
A total of 879 studies were imported from the databases. Among these, 41 papers were screened for full text and 17 meet the inclusion criteria. Among them, pooled results showed 42% lower odds of occurrence of complications in the LP group (OR 0.58, CI 0.42-0.80) compared to TVP group. Notably, 70% lower odds of device dislodgment (OR 0.30, CI 0.21-0.43), 46% lower odds of re-intervention (OR 0.54, CI 0.45-0.64), 87% lower odds of pneumothorax (OR 0.13, CI 0.03-0.57), albeit, 2.65 times higher odds of pericardial effusion (OR 2.65, CI 1.49-4.70) were observed in the LP group.
CONCLUSIONS CONCLUSIONS
This meta-analysis showed LP to be a significantly safer modality compared to TVP, in terms of re-intervention, device dislodgment, pneumothoraxes, and overall complications. However, there were higher rates of pericardial effusion in the LP group. There was a diverse number of patients included, and all studies were observational. Randomized trials are needed to validate our findings.

Identifiants

pubmed: 37106267
doi: 10.1007/s10840-023-01550-8
pii: 10.1007/s10840-023-01550-8
doi:

Types de publication

Meta-Analysis Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2165-2175

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Zucchelli G, Tolve S, Barletta V, Di Cori A, Parollo M, De Lucia R, et al. Comparison between leadless and transvenous single-chamber pacemaker therapy in a referral centre for lead extraction. J Interv Card Electrophysiol. 2021;61:395–404. https://doi.org/10.1007/S10840-020-00832-9 .
doi: 10.1007/S10840-020-00832-9 pubmed: 32712901
Piccini JP, Stromberg K, Jackson KP, Laager V, Duray GZ, El-Chami M, et al. Long-term outcomes in leadless Micra transcatheter pacemakers with elevated thresholds at implantation: Results from the Micra Transcatheter Pacing System Global Clinical Trial. Hear Rhythm. 2017;14:685–91. https://doi.org/10.1016/J.HRTHM.2017.01.026 .
doi: 10.1016/J.HRTHM.2017.01.026
Reddy VY, Exner DV, Doshi R, Tomassoni G, Bunch TJ, Estes NAM, et al. Primary results on safety and efficacy from the LEADLESS II–phase 2 worldwide clinical trial. Clin Electrophysiol. 2022;8:115–7. https://doi.org/10.1016/J.JACEP.2021.11.002 .
doi: 10.1016/J.JACEP.2021.11.002
Vaidya VR, Dai M, Asirvatham SJ, Rea RF, Thome TM, Srivathsan K, et al. Real-world experience with leadless cardiac pacing. Pacing Clin Electrophysiol. 2019;42:366–73. https://doi.org/10.1111/PACE.13601 .
doi: 10.1111/PACE.13601 pubmed: 30632622
Tachibana M, Banba K, Matsumoto K, Ohara M. The feasibility of leadless pacemaker implantation for superelderly patients. Pacing Clin Electrophysiol. 2020;43:374–81. https://doi.org/10.1111/PACE.13894 .
doi: 10.1111/PACE.13894 pubmed: 32134134
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA, et al. statement: an updated guideline for reporting systematic reviews. BMJ. 2020;2021:372. https://doi.org/10.1136/BMJ.N71 .
doi: 10.1136/BMJ.N71
Shrestha D, Shtembari J, Awal S, Gyawali P, Raut A. Leadless pacemaker versus conventional transvenous pacemaker: systematic review and meta-analysis. PROSPERO 2022 CRD42022325376. 2022. https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=325376 . Accessed 16 Dec 2022.
Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. n.d. www.covidence.org . Accessed 13 May 2021.
critical-appraisal-tools - Critical Appraisal Tools | Joanna Briggs Institute. n.d. https://jbi.global/critical-appraisal-tools . Accessed 28 Nov 2021.
Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; 2019.
RevMan for non-Cochrane reviews | Cochrane Training. n.d. https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman/revman-non-cochrane-reviews . Accessed 26 Jan 2021.
El-Chami MF, Bockstedt L, Longacre C, Higuera L, Stromberg K, Crossley G, et al. Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up. Eur Heart J. 2022;43:1207–15. https://doi.org/10.1093/EURHEARTJ/EHAB767 .
doi: 10.1093/EURHEARTJ/EHAB767 pubmed: 34788416
Beurskens NEG, Tjong FVY, De Bruin-Bon RHA, Dasselaar KJ, Kuijt WJ, Wilde AAM, et al. Impact of leadless pacemaker therapy on cardiac and atrioventricular valve function through 12 months of follow-up. Circ Arrhythmia Electrophysiol. 2019;12(5):e007124.  https://doi.org/10.1161/CIRCEP.118.007124 .
Cabanas-Grandío P, García Campo E, Bisbal F, García-Seara J, Pachón M, Juan-Salvadores P, et al. Quality of life of patients undergoing conventional vs leadless pacemaker implantation: a multicenter observational study. J Cardiovasc Electrophysiol. 2020;31:330–6. https://doi.org/10.1111/JCE.14322 .
doi: 10.1111/JCE.14322 pubmed: 31840881
Cantillon DJ, Dukkipati SR, Ip JH, Exner DV, Niazi IK, Banker RS, et al. Comparative study of acute and mid-term complications with leadless and transvenous cardiac pacemakers. Hear Rhythm. 2018;15:1023–30. https://doi.org/10.1016/j.hrthm.2018.04.022 .
doi: 10.1016/j.hrthm.2018.04.022
Martinez-Sande JL, Garcia-Seara J, Gonzalez-Melchor L, Rodriguez-Mañero M, Baluja A, Fernandez-Lopez XA, et al. Conventional single-chamber pacemakers versus transcatheter pacing systems in a “real world” cohort of patients: a comparative prospective single-center study. Indian Pacing Electrophysiol J. 2021;21:89–94. https://doi.org/10.1016/J.IPEJ.2020.12.004 .
doi: 10.1016/J.IPEJ.2020.12.004 pubmed: 33418071 pmcid: 7952774
Moore SKL, Chau KH, Chaudhary S, Rubin G, Bayne J, Avula UMR, et al. Leadless pacemaker implantation: a feasible and reasonable option in transcatheter heart valve replacement patients. Pacing Clin Electrophysiol. 2019;42:542–7. https://doi.org/10.1111/PACE.13648 .
doi: 10.1111/PACE.13648 pubmed: 30829416 pmcid: 6476663
Okuyama K, Izumo M, Sasaki K, Kuwata S, Kaihara T, Watanabe M, et al. Comparison in clinical outcomes between leadless and conventional transvenous pacemaker following transcatheter aortic valve implantation. J Invasive Cardiol. 2020;32:400–4.
pubmed: 32999094
Pagan E, Gabriels J, Khodak A, Chang D, Beldner S, Epstein LM, et al. Safety of leadless pacemaker implantation in the very elderly. Hear Rhythm. 2020;17:2023–8. https://doi.org/10.1016/j.hrthm.2020.05.022 .
doi: 10.1016/j.hrthm.2020.05.022
Palmisano P, Guido A, Panico V, Chiuri MD, Chiarillo MV, Sergi C, et al. Leadless pacemaker versus transvenous single-chamber pacemaker therapy: peri-procedural aspects, utilization of medical resources and patient acceptance. Expert Rev Med Devices. 2021;18:483–91. https://doi.org/10.1080/17434440.2021.1921573 .
doi: 10.1080/17434440.2021.1921573 pubmed: 33888044
Reynolds D, Duray GZ, Omar R, Soejima K, Neuzil P, Zhang S, et al. A leadless intracardiac transcatheter pacing system. N Engl J Med. 2016;374:533–41. https://doi.org/10.1056/NEJMOA1511643 .
doi: 10.1056/NEJMOA1511643 pubmed: 26551877
Sanchez R, Nadkarni A, Buck B, Daoud G, Koppert T, Okabe T, et al. Incidence of pacing-induced cardiomyopathy in pacemaker-dependent patients is lower with leadless pacemakers compared to transvenous pacemakers. J Cardiovasc Electrophysiol. 2021;32:477–83. https://doi.org/10.1111/JCE.14814 .
doi: 10.1111/JCE.14814 pubmed: 33205561
Sasaki K, Togashi D, Nakajima I, Suchi T, Nakayama Y, Harada T, et al. Clinical outcomes of non-atrial fibrillation bradyarrhythmias treated with a ventricular demand leadless pacemaker compared with an atrioventricular synchronous transvenous pacemaker—a propensity score-matched analysis. Circ J. 2022;86(8):1283–91. https://doi.org/10.1253/CIRCJ.CJ-21-0889 .
Yarlagadda B, Turagam MK, Dar T, Janagam P, Veerapaneni V, Atkins D, et al. Safety and feasibility of leadless pacemaker in patients undergoing atrioventricular node ablation for atrial fibrillation. Hear Rhythm. 2018;15:994–1000. https://doi.org/10.1016/J.HRTHM.2018.02.025 .
doi: 10.1016/J.HRTHM.2018.02.025
Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Hear Rhythm. 2016;13:2272–8. https://doi.org/10.1016/j.hrthm.2016.09.027 .
doi: 10.1016/j.hrthm.2016.09.027
Lakkireddy D, Knops R, Atwater B, Neuzil P, Ip J, Gonzalez E, et al. A worldwide experience of the management of battery failures and chronic device retrieval of the Nanostim leadless pacemaker. Hear Rhythm. 2017;14:1756–63. https://doi.org/10.1016/j.hrthm.2017.07.004 .
doi: 10.1016/j.hrthm.2017.07.004
Breeman KTN, Oosterwerff EFJ, Dijkshoorn LA, Salavati A, Beurskens NEG, Wilde AAM, et al. Real-world long-term battery longevity of Micra leadless pacemakers. J Interv Card Electrophysiol. 2022. https://doi.org/10.1007/s10840-022-01447-y .
Li Y, Xing Q, Xiaokereti J, Chen C, Zhang J, Zhou X, et al. Right ventriculography improves the accuracy of leadless pacemaker implantation in right ventricular mid-septum. J Interv Card Electrophysiol. 2022. https://doi.org/10.1007/s10840-022-01399-3 .
Sharma P, Singh Guleria V, Bharadwaj P, Datta R. Assessing safety of leadless pacemaker (MICRA) at various implantation sites and its impact on paced QRS in Indian population. Indian Heart J. 2020;72:376–82. https://doi.org/10.1016/j.ihj.2020.08.001 .
doi: 10.1016/j.ihj.2020.08.001 pubmed: 33189197 pmcid: 7670279

Auteurs

Jurgen Shtembari (J)

Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL, USA.

Dhan Bahadur Shrestha (DB)

Department of Internal Medicine, Mount Sinai Hospital, Chicago, IL, USA. medhan75@gmail.com.

Shila Awal (S)

Department of Internal Medicine, Suryabinayak Municipal Hospital, Suryabinayak, Nepal.

Anuradha Raut (A)

Department of Internal Medicine, Nepal Medical College, Kathmandu, Nepal.

Pratik Gyawali (P)

Department of Internal Medicine, Om Saibaba Memorial Hospital, Kathmandu, Nepal.

Temidayo Abe (T)

Department of Internal Medicine, Division of Cardiology, Vanderbilt University Medical Center, Nashville, TN, USA.

Nimesh K Patel (NK)

Department of Internal Medicine, Division of Cardiology, School of Medicine, Virginia Commonwealth University, Richmond, VA, USA.

Abhishek Deshmukh (A)

Department of Cardiology, Division of Electrophysiology, Mayo Clinic, Rochester, MN, USA.

Dinesh Voruganti (D)

Department of Internal Medicine, Division of Cardiology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Prashant Dattatraya Bhave (PD)

Department of Cardiology, Division of Electrophysiology, Wake Forest University School of Medicine, Winston Salem, NC, USA.

Patrick Whalen (P)

Department of Cardiology, Division of Electrophysiology, Wake Forest University School of Medicine, Winston Salem, NC, USA.

Naga Venkata K Pothineni (NVK)

Department of Cardiology, Kansas City Heart Rhythm Institute, Overland Park, KS, USA.

Ghanshyam Shantha (G)

Department of Cardiology, Division of Electrophysiology, Wake Forest University School of Medicine, Winston Salem, NC, USA. gpalaman@wakehealth.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH